Literature DB >> 15180451

Regulators of G protein signaling: potential drug targets for controlling cardiovascular and immune function.

H Cho1, K Harrison, J H Kehrl.   

Abstract

Heterotrimeric G-protein-coupled receptors (GPCRs) mediate a wide variety of organismal functions ranging from vision, olfaction, and gustation to the development and physiology of the cardiovascular, neuronal, and immune system. Naturally they are targets of a large number of therapeutic drugs. The regulators of G protein signaling (RGS) are a family of diverse proteins that regulate the GPCR-mediated signaling pathways principally by acting as GTPase activating proteins (GAPs) for the alpha subunit of the heterotrimeric G-proteins. Certain members of the RGS family contain multiple domains and motifs that mediate interactions with other signaling molecules, thus linking GPCR-dependent and GPCR-independent signaling pathways. Because of their ability to fine-tune vital GPCR-mediated processes and recent findings linking them to brain disorders, retinitis pigmentosa, and cancer RGS proteins have become excellent candidates for new drug discovery. The focus of this review is to discuss the roles of the RGS proteins in the development and normal physiology of cardiovascular and immune system, and to explore their potential as drug targets useful for the treatment of pathological conditions of the cardiovascular and immune systems.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15180451     DOI: 10.2174/1568008043339938

Source DB:  PubMed          Journal:  Curr Drug Targets Immune Endocr Metabol Disord        ISSN: 1568-0088


  8 in total

1.  Pleiotropic phenotype of a genomic knock-in of an RGS-insensitive G184S Gnai2 allele.

Authors:  Xinyan Huang; Ying Fu; Raelene A Charbeneau; Thomas L Saunders; Douglas K Taylor; Kurt D Hankenson; Mark W Russell; Louis G D'Alecy; Richard R Neubig
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

Review 2.  Regulators of G-protein signaling and their Gα substrates: promises and challenges in their use as drug discovery targets.

Authors:  Adam J Kimple; Dustin E Bosch; Patrick M Giguère; David P Siderovski
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

Review 3.  The evolution of regulators of G protein signalling proteins as drug targets - 20 years in the making: IUPHAR Review 21.

Authors:  B Sjögren
Journal:  Br J Pharmacol       Date:  2017-02-08       Impact factor: 8.739

4.  PDGF-dependent regulation of regulator of G protein signaling-5 expression and vascular smooth muscle cell functionality.

Authors:  Jagadambika J Gunaje; Arya J Bahrami; Stephen M Schwartz; Guenter Daum; William M Mahoney
Journal:  Am J Physiol Cell Physiol       Date:  2011-05-18       Impact factor: 4.249

5.  Interferonβ-1b Induces the Expression of RGS1 a Negative Regulator of G-Protein Signaling.

Authors:  Tiffany Tran; Pedro Paz; Sharlene Velichko; Jill Cifrese; Praveen Belur; Ken D Yamaguchi; Karin Ku; Parham Mirshahpanah; Anthony T Reder; Ed Croze
Journal:  Int J Cell Biol       Date:  2011-01-17

6.  FBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex.

Authors:  Benita Sjögren; Steven Swaney; Richard R Neubig
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

7.  Combining genetic mapping with genome-wide expression in experimental autoimmune encephalomyelitis highlights a gene network enriched for T cell functions and candidate genes regulating autoimmunity.

Authors:  Melanie Thessen Hedreul; Steffen Möller; Pernilla Stridh; Yask Gupta; Alan Gillett; Amennai Daniel Beyeen; Johan Öckinger; Sevasti Flytzani; Margarita Diez; Tomas Olsson; Maja Jagodic
Journal:  Hum Mol Genet       Date:  2013-07-29       Impact factor: 6.150

8.  RGS12 is a novel tumor suppressor in osteosarcoma that inhibits YAP-TEAD1-Ezrin signaling.

Authors:  Yang Li; Min Liu; Shuting Yang; Ashley M Fuller; T S Karin Eisinger-Mathason; Shuying Yang
Journal:  Oncogene       Date:  2021-03-08       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.